Citations

Clear

623 citation(s) found for "Torres, V".

Fat-Free Mass Accretion: Limits, Targets, and Best Practices
Trexler, Eric T. , Torres, Marcella, Potter, Nicholas D., Ketterly, Jennifer, Kerkow-Provo, Zachary, Lane, Michael T., Jagim, Andrew R.

Mayo Clinic

Strength & Conditioning Journal | July 1, 2026 | Volume: 48 | Issue: 4 | Pages: 521-539

10.1519/ssc.0000000000000986 Get It

ABSTRACT This review examines physiological limits, longitudinal projections, and best practices for muscle hypertrophy with a focus on bodybuilding and physique sport. Recurring body composition assessments using multicompartment models are recommended for monitoring short-term fat-free mass (FFM) changes and long-term muscular development. Normative data indicate that drug-free male athletes typically gain roughly 1.4 kg of FFM over 12 weeks of resistance training, with an interquartile range of 1–2 kg. A practical upper limit for FFM index in drug-free male athletes is approximately 28.5, although higher values have been observed in the context of elevated adiposity or anabolic androgenic steroid use. Female athletes tend to have roughly 70% less FFM at baseline but make proportionally similar FFM gains in response to resistance training. The present review models plausible short-term and long-term growth trajectories for both male and female lifters. Training practices that optimize hypertrophy include moderate loads (6–12 repetition maximum), training near muscular failure, and sufficient weekly volume (12–30 fractional sets per muscle group). Nutritional factors include maintaining modest caloric surpluses (0.1–0.25% body weight gain weekly), adequate protein intake (1.6–2.2 g/kg/d), sufficient carbohydrate intake (≥3 g/kg/d), and moderate fat intake (0.5–1.5 g/kg/d). Creatine and protein supplementation provide established hypertrophic benefits, while evidence for other supplements remains inconclusive.
Plasma Cell Mucositis: A 20‐Year Retrospective Review at a Tertiary Center
Torres, Miguel A. Aristizabal , Larrinaga, Jessi M. , Bodiford, Katherine, Tolaymat, Leila, Aristizabal, Miguel A , Aristizabal, Miguel, Bodiford, Katherine J., Sokumbi, Olayemi , Tolaymat, Leila

Mayo Clinic

JEADV Clinical Practice | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jvc2.70390 Get It

ABSTRACT Background Plasma cell mucositis (PCM) is a rare, chronic inflammatory condition of mucosal surfaces that is likely underdiagnosed and underreported, with limited data on its clinical characteristics, extracavitary involvement, and treatment outcomes. Objectives To characterize the clinical presentation, comorbidities, and treatment patterns of PCM in a cohort of patients from a tertiary care center. Methods We conducted a retrospective cohort study of histopathologically confirmed PCM cases diagnosed at a tertiary care center between 2004 and 2024. Cases were identified based on clinicopathologic correlation demonstrating a polyclonal plasma cell–rich infiltrate. Demographic data, clinical features, comorbidities, laboratory findings, and treatment outcomes were collected and analyzed descriptively. Results Ten patients were included, of whom 7 (70%) were aged ≥ 50 years and 6 (60%) were male. Genital involvement was observed in 6 patients (60%), whereas oral involvement occurred in 4 (40%). Symptom duration exceeded 2 years in 6 patients (60%). Concurrent malignancies were identified in 4 patients (40%), and autoimmune conditions in 2 (20%). Treatment responses were heterogeneous; topical corticosteroids were the most consistently effective therapy, while systemic immunosuppressive agents were required in 3 patients (30%) with variable outcomes. Patch testing identified contact allergens in 2 patients, with improvement following allergen avoidance. Conclusions PCM is a rare and often chronic condition with heterogeneous clinical manifestations and variable therapeutic responses. Genital involvement may be more common than previously recognized. Management remains challenging, highlighting the need for improved understanding of disease pathogenesis and development of more effective treatment strategies.
Targeting liver metastases in uveal melanoma: ATX-LPA mediated immunosuppression and novel therapeutic approaches
Turner, Jacqueline A. , D’Antonio, Marc, Montane, Heather N. , MacBeth, Morgan, Katsnelson, Elizabeth, Robinson, William A., Couts, Kasey L. , Torres, Raul M., A Turner, Jacqueline, D’Antonio, Marc A. , MacBeth, Morgan L. , Robinson, William A., Tobin, Richard P. , Markovic, Svetomir N.

Mayo Clinic

Frontiers in Immunology | June 18, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1829486 | PMID 42396445 Get It

Introduction Uveal melanoma has a marked tropism for the liver where immune tolerance facilitates metastatic progression and resistance to immunotherapy. Impaired CD8 + T cell immunosurveillance is a central determinant of disease progression in uveal melanoma, yet the underlying mechanisms driving liver-mediated immune subpression and hepatic metastasis are not fully understood. Here, we investigate molecular pathways that regulated hepatic CD8 + T cell function and evaluate clinical outcomes associated with liver-directed therapy. Methods Expression of autotaxin (ATX), the expression responsible for generating lysophosphatidic acid (LPA), was evaluated in hepatic resident cell populations. ATX transcript levels were assessed in CD8 + T cells isolated from hepatic metastases and compared with matched peripheral blood and healthy donor control. Antigen-specific effector CD8 + T cells were used to characterize downstream signaling responses to LPA stimulation. Functional studies evaluating cytokine production during chronic antigen exposure were performed using CD8 + T cells from LPA receptor 5-deficient ( Lpar5 -/- ) mice. Results We identify the autotaxin-lysophosphatidic acid (ATX-LPA) axis as a prominent immunoregulatory pathway in the metastatic hepatic tumor microenvironment. ATX, the enzyme responsible for LPA production, is constitutively expressed by hepatic resident cells, is detectable on Kupffer cells and is associated with increased immunosubpressive markers. CD8 + T cells isolated from hepatic metastasis in a patient with uveal melanoma display markedly elevated ATX transcripts compared to matched peripheral blood (>5 log 2 fold change) and healthy controls. Using antigen-specific effector CD8 + T cells, we demonstrate LPA signaling induces low level, persistent ERK phosphorylation distinct from canonical antigen-induced TCR signaling. Genetic deletion of the LPA receptor 5 ( Lpar5 -/- ) on CD8 + T cells restores CD8 T cell percentages and cytokine function during persistent antigen stimulation in the presence of LPA. Discussion These findings define an ATX-LPA mechanisms of dysfunctional ERK signaling that may contribute to hepatic immune subpression in uveal melanoma. We highlight this pathway as a rational therapeutic target alongside liver-directed clinical interventions.
GLUT9b- and ABCG2-mediated collecting duct urate transport uncovers a vasopressin-independent mechanism of renal water reabsorption
Hadla, Mohamad , Mardirossian, Jean Marc , Bichet, Daniel, Borghol, Abdul Hamid , Abboud, Georges, Ghanem, Ahmad , Chini, Eduardo N., Harris, Peter, Alper, Seth L., Vallon, Volker , Chini, Eduardo, Hadla, Mohamad , Vallon, Volker , Bichet, Daniel Georges , Abboud, Georges , Chini, Eduardo N. , Harris, Peter C. , Torres, Vicente E. , Alper, Seth L. , Chebib, Fouad T.

Mayo Clinic

Journal of Clinical Investigation | June 16, 2026 | Volume: 136 | Issue: 14 | Pages: No page available

10.1172/jci197021 | PMID 42298327 Get It

Renal water reabsorption is classically regulated by vasopressin V2 receptor (V2R) signaling through cyclic AMP and protein kinase A, driving apical accumulation of aquaporin-2 (AQP2). However, collecting duct water handling is also modulated by vasopressin-independent mechanisms. Here, we examined intracellular soluble urate as a vasopressin-independent regulator of AQP2 trafficking. Intracellular urate accumulation in collecting duct cells was mediated by enhanced apical urate uptake via GLUT9b and reduced apical urate efflux through ABCG2, triggering phosphodiesterase-4 activation, reduced cAMP, and downstream AMP-activated protein kinase (AMPK) activation. The resulting AQP2 accumulation at the apical membrane was independent of V2R signaling, required ongoing endocytosis, and was associated with features of postendocytic apical trafficking of internalized AQP2. In vivo ABCG2 inhibition with probenecid increased apical AQP2 abundance and markedly attenuated tolvaptan-induced polyuria in both wild-type and Pkd1 RC/RC autosomal dominant polycystic kidney disease (ADPKD) mice in a uricase-independent manner while preserving tolvaptan’s ADPKD-modifying efficacy. In a phase II trial with tolvaptan-treated patients with ADPKD, probenecid reduced urine volume and nocturia frequency. Together, these findings support a vasopressin-independent urate/AMPK/AQP2 pathway that regulates renal water handling and, in a preclinical ADPKD model, can uncouple cyst growth attenuation from the dose-limiting aquaretic effects of V2R antagonism.
PHLPP Signaling Regulates NaV1.8 Innervation in Post-traumatic Osteoarthritis (PTOA) (P7-14.001)
Torres, Haydee, Bradley, Elizabeth, Li, Xiaodong , Zars, Elizabeth, Oviedo, Manuela , Weaver, Samantha, Peralta-Herrera, Eduardo , Peters, Christopher, Staff, Nathan, Westendorf, Jennifer, Torres, Haydee M., Li, Xiaodong, Zars, Elizabeth L. , Weaver, Samantha, Westendorf, Jennifer J.

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217385 Get It

EBUS ‐Guided Incidental Finding of Pulmonary Vein Thrombosis: A Case Report and Literature Review
Alqawasma, M, Yesilkaya, Y E, Rojas-Zapata, Tatiana A. , Murillo‐Torres, Regina, Lee-Mateus, A Yu, Vu, L, Fleissner, Zachary J., Husta, B C, Abia‐Trujillo, David , Fernandez-Bussy, S, Lee‐Mateus, Alejandra Yu , Vu, Linh H. , Alqawasma, Mohammed A., Yesilkaya, Yunus E, Yu Lee-Mateus, Alejandra , Vu, Linh H , Abia-Trujillo, David , Murillo‐Torres, Regina M.

Mayo Clinic

Respirology Case Reports | June 4, 2026 | Volume: 14 | Issue: 6 | Pages: No page available

10.1002/rcr2.70612 | PMID 42369328 Get It

ABSTRACT Pulmonary vein thrombosis (PVT) is an uncommon but potentially fatal condition that is often underdiagnosed due to nonspecific clinical presentation. We report a case of a 47‐year‐old woman with a thrombus in the right inferior pulmonary vein incidentally found during a robotic‐assisted bronchoscopy biopsy (RAB) and endobronchial ultrasound (EBUS) performed for mediastinal evaluation and lymph node sampling. PVT was confirmed with computed tomography pulmonary angiography, and the patient was successfully treated with anticoagulation therapy. A review of the literature revealed that reports of PVT detected via EBUS are exceedingly rare and usually malignant in nature. To our knowledge, this is the first peer‐reviewed case report describing PVT identified incidentally during EBUS, underscoring the potential of this technique to reveal clinically significant vascular abnormalities.
Toward a Standardized Definition of Distal (Ileal) Metabolic Bariatric Surgery: An International Modified Delphi Consensus
Leon-Ballesteros, Guillermo Ponce de, Pouwels, Sjaak, Ghanem, Omar M., Arana, Sebastián, Rodriguez, Christian, Aceves, Manuel , Berry, Marcos, Brown, Wendy, Caiazzo, Robert, Carbajo, Miguel A., Cottam, Daniel, Dib, Victor, Dillemans, Bruno, Elli, Enrique F., Estrada, Roberto, Ferraro, Ariel, Gutiérrez-Rojas, Carlos A., Herrera, Miguel F., Huang, Chih‐Kun , Panagiotis, Lainas, MARTINEZ, SANDY, NAVARRETE, SALVADOR, Ortiz, Elias, Pantoja, Juan Pablo, Parmar, Chetan, Pattou, F , Ponce, Jaime , Ramirez, Christian, Ribeiro, Rui , Rodriguez-Esquerra, Antonio, Romero, Gustavo, Rotundo, Adriana, Salvi, Prashant, Sanchez-Pernaute, Andres, Santoro, Sérgio , Topart, Philippe, Torres, Antonio, Ungson, Gilberto , Weiner, Sylvia, Zerrweck, Carlos, León‐Ballesteros, Guillermo Ponce de , Pouwels, Sjaak , Ghanem, Omar M. , Arana-Garza, Sebastián, Angrisani, Luigi , Berry, Marcos A. , Brown, Wendy, Caiazzo, Robert J. , Carbajo, Miguel‐A., Chiappetta, Sonja , Cottam, Daniel Rhead , Dib, Victor Ramos Mussa , Dillemans, Bruno , Elli, Enrique F. , Ferraro, Ariel, Gutiérrez-Rojas, Carlos Alberto , Herrera, Miguel F. , Kermansaravi, Mohammad , Kurian, Marina S. , Laïnas, Panagiotis , Madalosso, Carlos Augusto Scussel , Martinez, Sandy, Parmar, Chetan D. , Salvi, Prashant H., Sánchez-Pernaute, Andrés , Topart, Philippe A. , Weiner, Sylvia R., Zerrweck, Carlos

Mayo Clinic

No container title available | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9765725/v1 Get It

Abstract Background Distal (ileal) metabolic bariatric surgeries (DMBS) have gained increasing adoption due to their enhanced metabolic effects. However, the absence of standardized definitions, classification, and clinical indications limits their consistent application. This consensus aimed to establish an international consensus on the definition, classification, indications, and postoperative management of DMBS. Methods A three-round modified Delphi study was conducted including international expert surgeons from 16 countries. A total of 98 statements were developed across three domains: procedural characteristics, patient selection, and postoperative follow-up. Consensus was defined as ≥75% agreement. Statements not reaching consensus were revised and resubmitted. Results Consensus was achieved on 81 statements. DMBS were defined as procedures involving gastro-ileal or duodeno-ileal bypass, emphasizing ileal stimulation as a key metabolic mechanism. Procedures with a common channel ≤350 cm, including single-anastomosis duodenal-ileal with SG (SADI-S), single anastomosis sleeve-ileal transit bipartition (SASI), sleeve gastrectomy with Roux-en-Y transit bipartition (SG+TB), and biliopancreatic diversion with duodenal switch (BPD-DS), as well as one-anastomosis gastric bypass (OAGB) with biliopancreatic limb > 50% of total small bowel length were classified as DMBS. Routine measurement of total small bowel length was strongly recommended. DMBS were considered appropriate as primary procedures in patients with BMI ≥40 kg/m² with comorbidities, a BMI ≥50–60 kg/m², irrespective of the presence of comorbidities, and as revisional options for suboptimal clinical response (SoCR), recurrent weight gain (RWG), or persistent metabolic disease. Comprehensive preoperative and multidisciplinary evaluation was deemed mandatory, and liver cirrhosis, heart failure, end-stage kidney disease, and inflammatory bowel disease were considered contraindications. Postoperative care requires lifelong multidisciplinary follow-up, with increased attention to nutritional deficiencies and supplementation. Conclusions This consensus provides a standardized framework for DMBS, supporting harmonization of practice and improved patient safety.
Data from a real-world study: Association of CDCP1 expression level with survival outcomes in mCRC patients treated with bevacizumab or cetuximab plus chemotherapy.
Goretsky, Yitzhar Efraim, Yang, Yan, Bartolini, Michela, Soni, Shivani, Mittal, Pooja, Torres-Gonzalez, Lesly, Shah, Unnati Hemant, Ho-Lo, Jae, Trujillo, Steve Soto , Zhang, Wu, Venook, Alan P., Algaze, Sandra, Millstein, Joshua , Lenz, Heinz-Josef, Torres‐Gonzalez, Lesly , Goretsky, Yitzhar, Yang, Yan , Bartolini, Michela, Soni, Shivani , Mittal, Pooja, Ou, Fang‐Shu , Lo, Jae Ho, Venook, Alan P. , Algaze, Sandra , Lenz, Heinz‐Josef

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3593-3593

10.1200/jco.2026.44.16_suppl.3593 Get It

3593 Background: CUB domain-containing protein 1 (CDCP1) is a transmembrane protein shown to be over-expressed in colorectal cancer (CRC), with an important role in tumor initiation, growth and metastasis. Through interactions with EGFR, CDCP1 promotes nuclear translocation of the key regulators of Wnt signaling, β-catenin and E-cadherin. High CDCP1 expression has been associated with poor survival outcomes in multiple solid tumors but data in CRC remains limited. We investigated associations between CDCP1 level and survival outcomes in patients with metastatic CRC (mCRC) in the phase III clinical trial CALGB/SWOG 80405 (Alliance). Methods: Data from 433 mCRC patients in the CALGB/SWOG 80405 (Alliance) trial were analyzed. Patients received bevacizumab (n = 226) or cetuximab (n = 207) plus chemotherapy as 1st-line treatment. Tumor RNA was extracted from FFPE samples and processed through the HiSeq 2500 (Illumina) platform. Overall survival (OS) and progression free survival (PFS) curves were evaluated in all treatment subgroups and stratified according to high or low CDCP1 expression. Likelihood ratio tests, hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated using Cox proportional hazards multivariate models, adjusting for age, sex, ECOG performance status, tumor location, number of metastatic sites, KRAS status, consensus molecular subtypes, and treatment arm. Results: Overall, low CDCP1 expression was associated with better OS compared to high expression (HR = 1.38; 95% CI 1.07-1.77; 35.8 vs 25.0 months, p = 0.045). Subgroup analysis re-demonstrated this pattern in males (HR = 1.64; 95% CI 1.64-2.28; 35.9 vs 23.6 months, p = 0.01), patients with MSS tumors (HR = 1.56; 95% CI 1.17-2.08; 36.7 vs 25.1 months, p = 0.0094), and patients treated with cetuximab+FOLFOX (HR = 1.79; 95% CI 1.16-2.77; 40.8 vs 24.0 months, p = 0.03). The effect of CDCP1 expression on PFS was less pronounced. Relative to high expression, low expression was associated with better PFS in males (HR = 1.49; 95% CI 1.10-2.03; 13.1 vs 9.8 months, p = 0.027) and left-sided tumors (HR = 1.50; 95% CI 1.10-2.04; 14.4 vs 10.1 months, p = 0.034). Conclusions: Our findings represent real-world data of the predictive role of CDCP1 in patients with mCRC undergoing anti-EGFR or anti-VEGF treatment. Consistent with studies of other cancers, we show that low CDCP1 expression is predictive of better survival outcomes, with subgroup analysis revealing associations in males, MSS tumors, and left-sided tumors. Among treatment groups, low CDCP1 expression is predictive of better OS in cetuximab+FOLFOX-treated patients, a key finding given CDCP1’s close mechanistic ties to EGFR. Further studies should explore whether these associations are seen in other treatment modalities and whether CDCP1 blockade could represent a viable strategy in patients with high expression.